Abbott vs. DexCom: Which CGM Stock Is the Better Buy Now?

ABT edges DXCM on price-target upside and valuation, while both pursue CGM growth through innovation, adoption and strong liquidity.

Zacks Investment Research • 9 hours ago

Here's Why DexCom (DXCM) is a Strong Momentum Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Aug 21, 2026

The Big 3: PH, DXCM, UNP

Dan Deming discusses why he sees sideways action in the stock market continuing through next week, noting anticipating for the Fed's Jackson Hole meeting. As for Thursday's Big 3, he sees an opportunity in Parker-Hannifin (PH) closing its stock gap, Dexcom (DXCM) maintaining recent upward momentum, and Union Pacific (UNP) becoming a leader in the railroad industry's comeback.

Here's Why DexCom (DXCM) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • Aug 13, 2026

DXCM Stock Up Nearly 35% YTD: Will the Uptrend Continue in the Rest of 2026?

DXCM's 2026 rebound is backed by stronger growth, G7 15 Day adoption and broader CGM access, but competition and reimbursement remain key risks.

Zacks Investment Research • Aug 12, 2026

DXCM Rallies 52.5% in 3 Months. Can the Stock Keep Climbing From Here?

DexCom's 52.5% three-month rally is backed by earnings growth and margin gains, but premium valuation, competition and litigation raise the bar.

Zacks Investment Research • Aug 12, 2026

Can DexCom's Raised 2026 Outlook Sustain Stronger Margin Momentum?

DexCom raises its 2026 revenue and margin outlook as G7 15 Day efficiencies lift profitability, while FX and transition costs remain key tests.

Zacks Investment Research • Aug 12, 2026

Is DXCM Stock Worth Buying as Growth Improves but Valuation Stretches?

DexCom's broader CGM coverage, G7 15 Day rollout and rising margins support growth, but premium valuation, competition and litigation temper upside.

Zacks Investment Research • Aug 12, 2026

DexCom: Still A Cautious Buy Following Earnings

Dexcom (DXCM) delivered strong Q2/26 results with 13.1% revenue growth, 49.7% operating income growth, and raised FY26 guidance. DXCM's growth drivers include G7 system adoption, international expansion, and initiatives like 'Road to 100' targeting broader diabetes coverage. Margin improvements, ongoing share buybacks, and a robust balance sheet support DXCM's growth and capital allocation strategy.

Seeking Alpha • Aug 3, 2026

DexCom, Inc. (DXCM) Hit a 52 Week High, Can the Run Continue?

DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Investment Research • Aug 3, 2026